IL1R1 and diabetes mellitus: In support of our data, it has been shown that anakinra, an inhibitor of IL-1R1-mediated signaling, is sufficient to inhibit several pathological features related to DN in a similar mouse model of diabetes [14], further underscoring the importance to target this axis for the treatment of DN patients.